Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
Elvira Valera, Brian Spencer, Jerel Adam Fields, et al.
Acta Neuropathologica Communications (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Ageing as a risk factor for neurodegenerative disease
Yujun Hou, Xiuli Dan, Mansi Babbar, et al.
Nature Reviews Neurology (2019) Vol. 15, Iss. 10, pp. 565-581
Closed Access | Times Cited: 2374
Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1
K. A. Jellinger
Journal of Alzheimer s Disease (2017) Vol. 62, Iss. 3, pp. 1141-1179
Open Access | Times Cited: 172
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Changyoun Kim, Brian Spencer, Edward Rockenstein, et al.
Molecular Neurodegeneration (2018) Vol. 13, Iss. 1
Open Access | Times Cited: 135
Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy
Shunsuke Koga, Dennis W. Dickson
Journal of Neurology Neurosurgery & Psychiatry (2017) Vol. 89, Iss. 2, pp. 175-184
Closed Access | Times Cited: 109
Multiple System Atrophy: Recent Developments and Future Perspectives
Wassilios G. Meissner, Pierre‐Olivier Fernagut, Benjamin Dehay, et al.
Movement Disorders (2019) Vol. 34, Iss. 11, pp. 1629-1642
Closed Access | Times Cited: 83
Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives
Giacomo Monzio Compagnoni, Alessio Di Fonzo
Acta Neuropathologica Communications (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 79
IFNγ drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy
Nicole J Corbin-Stein, Gabrielle Childers, Jhodi M. Webster, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 9
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model
Diptaman Chatterjee, Mansi A. Bhatt, David Butler, et al.
npj Parkinson s Disease (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 82
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders
Anne Messer, David C. Butler
Neurobiology of Disease (2019) Vol. 134, pp. 104619-104619
Open Access | Times Cited: 72
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Somin Kwon, Michiyo Iba, Changyoun Kim, et al.
Neurotherapeutics (2020) Vol. 17, Iss. 3, pp. 935-954
Open Access | Times Cited: 64
Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions
Seiji Kaji, Takakuni Maki, Tomoyuki Ishimoto, et al.
Translational Neurodegeneration (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 54
Inflammation in multiple system atrophy
Marta Leńska‐Mieciek, Natalia Madetko‐Alster, Piotr Alster, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease
Eva Nordström, Fredrik Eriksson, Jessica Sigvardson, et al.
Neurobiology of Disease (2021) Vol. 161, pp. 105543-105543
Open Access | Times Cited: 37
Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
Viswanath Das, John H. Miller, Alladi Charanraj Goud, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2078-2111
Open Access | Times Cited: 5
The neuropathology of multiple system atrophy and its therapeutic implications
Elvira Valera, Eliezer Masliah
Autonomic Neuroscience (2017) Vol. 211, pp. 1-6
Open Access | Times Cited: 43
Immunotherapies in Huntington's disease and α-Synucleinopathies
Oluwaseun Fatoba, Yosuke Ohtake, Takahide Itokazu, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 37
Emerging roles of microglia and neuroinflammation in Huntington's disease: From pathophysiology to clinical trials
Muna Abedrabbo, Pardis Kazemian, Colúm Connolly, et al.
Journal of Huntington s Disease (2025)
Closed Access
An update on MSA: premotor and non-motor features open a window of opportunities for early diagnosis and intervention
Viorica Chelban, Daniela Catereniuc, Daniela Aftene, et al.
Journal of Neurology (2020) Vol. 267, Iss. 9, pp. 2754-2770
Open Access | Times Cited: 29
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
Victoria Sidoroff, Pam Bower, Nadia Stefanova, et al.
Journal of Parkinson s Disease (2022) Vol. 12, Iss. 5, pp. 1369-1387
Open Access | Times Cited: 17
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
Chukwunonso K. Nwabufo, Omozojie P. Aigbogun
Journal of Neurology (2022) Vol. 269, Iss. 11, pp. 5762-5786
Open Access | Times Cited: 17
Neuroinflammation as modifier of genetically caused neurological disorders of the central nervous system: Understanding pathogenesis and chances for treatment
Janos Groh, Rudolf Martini
Glia (2017) Vol. 65, Iss. 9, pp. 1407-1422
Closed Access | Times Cited: 32
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Lisa Mészáros, Alana Hoffmann, Jeanette Wihan, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2775-2775
Open Access | Times Cited: 26
Associations of sleep disorders with cerebrospinal fluid α-synuclein in prodromal and early Parkinson’s disease
Xiaotong Wang, Huan Yu, Fengtao Liu, et al.
Journal of Neurology (2021) Vol. 269, Iss. 5, pp. 2469-2478
Closed Access | Times Cited: 22
Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloid‐β Cascade: Pros and Cons of Chemical and Biological Modalities
Jimin Kim, Hanna Jeon, Hye Yun Kim, et al.
ChemBioChem (2023) Vol. 24, Iss. 19
Closed Access | Times Cited: 7
Recent Advances in Clinical Trials in Multiple System Atrophy
David Bendetowicz, Margherita Fabbri, F. Sirna, et al.
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 4, pp. 95-112
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top